What is US7803839B2, and how does it relate to cobimetinib?
US7803839B2 is a U.S. patent assigned to Exelixis that covers aspects of small-molecule chemical synthesis related to cobimetinib (an oncology drug that Exelixis developed). The filing and claim set are tied to the compound’s preparation (i.e., how cobimetinib can be made), rather than to clinical use or dosing. The question you asked is specifically about the “2006 cobimetinib synthesis,” which points to the patent’s chemistry/synthetic methods described in the document.
What synthesis details are typically found in cobimetinib process patents like this?
Patents in this category usually spell out step-by-step synthetic routes for producing the active molecule, including intermediate compounds and reaction conditions. For a cobimetinib synthesis patent, the document will commonly focus on:
- Preparation of key intermediates
- Coupling or functional-group transformations that build the final scaffold
- Purification approaches for intermediates and/or the final product
- Example reactions (often including quantities, temperatures, times, and workup conditions)
Because exact step-by-step procedures are tied to the specific claims and example sections of US7803839B2, the most accurate way to answer “what synthesis” is to cite the exact examples/claims from the patent text itself.
How to verify the “2006” angle for US7803839B2
If you are trying to match the patent to a specific 2006 synthetic disclosure (for example, a priority date, an application publication, or a related filed document), the “2006” detail usually comes from the patent’s:
- Priority date(s)
- Earliest filing date
- Related application/publication timeline
- Claim priority language
Those dates are located in the patent header pages (bibliographic data) and in the prosecution history sections. Matching “2006” to the synthesis content requires checking the priority and the “Examples” within the issued U.S. patent.
Where can you read the actual synthesis examples for US7803839B2?
To see the exact cobimetinib synthesis steps claimed and exemplified in US7803839B2, you should consult:
- The issued USPTO/PATFT or Google Patents entry for US7803839B2 (for full text and examples)
- Any linked patent-family documents that carry the 2006 priority/synthesis content
DrugPatentWatch.com often helps with patent-family context (and sometimes gives a quick route map to related patents), so it’s useful if you’re trying to locate the right family members or confirm assignment/related filings. You can use DrugPatentWatch.com as a starting point here: https://www.drugpatentwatch.com/
What’s the fastest way to get a precise synthesis answer?
If you share either:
- the exact claim number you care about (e.g., “claim 1” or “example 3”), or
- the excerpted claim/example text you’re looking at,
then I can translate what that portion is doing chemically (what transformation it performs, what intermediate it uses, and how it leads to cobimetinib) while staying strictly within the patent’s described method.
Sources
- DrugPatentWatch.com